A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.

Trial Details

NCT ID
NCT07189403
Phase
PHASE1
Sponsor
Daiichi Sankyo
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • DS9051b
Locations (sample)
  • Sarasota, Florida, United States|27.33643,-82.53065
  • New York, New York, United States|40.71427,-74.00597
  • Providence, Rhode Island, United States|41.82399,-71.41283
  • Toulouse, France|43.60426,1.44367
  • Villejuif, France|48.7939,2.35992

Key Eligibility Criteria

  • Sign and date the main ICF, prior to the start of any trial-specific procedures.
  • Adults ≥18 years of age at the time the ICF is signed (Follow local regulatory requirements if the legal age of consent for trial participation is …
  • Histologically confirmed diagnosis of ACC or adenocarcinoma of the prostate
  • ECOG PS of 0 or 1 assessed no more than 14 days prior to C1D1. (ECOG PS of 2 due to cancer pain is acceptable)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →